AbbVie makes medicines for immune diseases, brain and nerve conditions and cancer, plus Botox. Its two immune drugs, Skyrizi and Rinvoq, brought in $8.48 billion of its $17.40 billion of revenue in the third quarter of 2026, as sales of its older drug Humira kept falling.
AbbVie and J&J's Janssen unit develop and sell the cancer drug Imbruvica together and share the profits. In the US, Janssen's share was $158 million in the third quarter of 2026; outside the US, J&J sells it and AbbVie's share was $182 million.
What to watch: Imbruvica sales, down 26% to $522 million.
Skyrizi, with $5.78 billion of sales in the third quarter of 2026, and Rinvoq, with $2.71 billion. Together they were about 42% of revenue in 2025.
Does AbbVie still sell Humira?
Yes, but sales fell 31% to $683 million in the third quarter of 2026 after it lost its exclusive US rights.
Who did AbbVie buy in 2026?
Apogee Therapeutics, for about $10.9 billion in cash, completed in September 2026. It adds an eczema drug in late-stage testing.
Read every connection
All 8 connections as cards, with sources. It's the same detail you get by tapping a box on the map.Show allHide
Suppliers
The companies AbbVie relies on to make what it sells, with sources.
Johnson & Johnson
Imbruvica partner
Size$522 million of Imbruvica sales (Q3 2026)
AbbVie and J&J's Janssen unit develop and sell the cancer drug Imbruvica together and share the profits. In the US, Janssen's share was $158 million in the third quarter of 2026; outside the US, J&J sells it and AbbVie's share was $182 million.
What to watch: Imbruvica sales, down 26% to $522 million.
AbbVie and Genentech, part of Roche, develop and sell the cancer drug Venclexta together. Genentech's share of profits and royalties was $284 million in the first quarter of 2026.
What to watch: How the profit split changes as Venclexta grows.
Epkinly, a cancer drug, is developed by AbbVie and Genmab together. Its sales rose 58% to $108 million in the third quarter of 2026, with US profits shared.
What to watch: Whether Epkinly becomes a large seller.
AbbVie bought Apogee for about $10.9 billion in cash in September 2026. Its lead drug, zumilokibart, is in late-stage testing for the skin disease eczema and may need dosing only every three or six months.
Three wholesalers, McKesson, Cardinal Health and Cencora, handled substantially all of AbbVie's US drug sales in 2025, with one taking up to 43% of US gross revenue. The US was $13.33 billion of third-quarter 2026 revenue.
What to watch: How much of US sales runs through each wholesaler.
Immunology revenue rose 16% to $9.17 billion in the third quarter of 2026. Skyrizi grew 23% to $5.78 billion and Rinvoq 24% to $2.71 billion, while Humira fell 31% to $683 million.
What to watch: Growth of the two drugs as Humira shrinks.
Neuroscience revenue, including Vraylar, Botox for medical uses, Ubrelvy and Qulipta, rose 19% to $3.39 billion. Aesthetics, including Botox Cosmetic and Juvederm, fell 1% to $1.18 billion.
Connections were last checked against company filings and news reports on Nov 21, 2026. Companies don't have to disclose every supplier or customer, so this map shows the most important ones that are publicly known, not every link.
How we check connections. StockTies is for information only. It is not investment advice. Spot something out of date? Tell us.